(Reuters) - The world's largest biotechnology company said it intends to include "top-line results," meaning important but limited data, from its so-called 145 study, which involved patients with the less common form of lung cancer who were receiving chemotherapy.
Amgen, which said on Tuesday it had replaced its chief financial officer, has seen its share price fall sharply in recent months after a number of setbacks -- including data from another clinical trial in which cancer patients taking Aranesp but not receiving chemotherapy had a worrisome death rate.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment